FDA approves first once-daily drug for ADHD
The US Food and Drug Administration (FDA) has approved extended-release methylphenidate hydrochloride oral suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD). Efficacy was determined in a randomized, double-blind, crossover study that showed improvement for both attention and behavior metrics for up to 12 hours in children aged 6 to 12 years diagnosed with ADHD compared with placebo. The once-daily treatment will be available in January 2013.
The US Food and Drug Administration (FDA) has approved extended-release methylphenidate hydrochloride oral suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD). Efficacy was determined in a randomized, double-blind, crossover study that showed improvement for both attention and behavior metrics for up to 12 hours in children aged 6 to 12 years diagnosed with ADHD compared with placebo. The once-daily treatment will be available in January 2013.
